Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals

AIDS. 2009 Jun 1;23(9):1176-9. doi: 10.1097/QAD.0b013e32832b4461.

Abstract

Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / blood
  • Anti-HIV Agents / pharmacokinetics
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Ritonavir / administration & dosage*
  • Ritonavir / blood
  • Ritonavir / pharmacokinetics
  • Saquinavir / administration & dosage*
  • Saquinavir / blood
  • Saquinavir / pharmacokinetics

Substances

  • Anti-HIV Agents
  • Saquinavir
  • Ritonavir